Infective endocarditis in adult patients with congenital heart disease.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
01 Jan 2023
Historique:
received: 09 07 2022
revised: 23 09 2022
accepted: 17 10 2022
pubmed: 24 10 2022
medline: 15 12 2022
entrez: 23 10 2022
Statut: ppublish

Résumé

Congenital Heart Disease (CHD) predisposes to Infective Endocarditis (IE), but data about characterization and prognosis of IE in CHD patients is scarce. The ESC-EORP-EURO-ENDO study is a prospective international study in IE patients (n = 3111). In this pre-specified analysis, adult CHD patients (n = 365, 11.7%) are described and compared with patients without CHD (n = 2746) in terms of baseline characteristics and mortality. CHD patients (73% men, age 44.8 ± 16.6 years) were younger and had fewer comorbidities. Of the CHD patients, 14% had a dental procedure before hospitalization versus 7% in non-CHD patients (p < 0.001) and more often had positive blood cultures for Streptococcus viridans (16.4% vs 8.8%, p < 0.001). As in non-CHD patients, IE most often affected the left-sided valves. For CHD patients, in-hospital mortality was 9.0% vs 18.1% in non-CHD patients (p < 0.001), and also, during the entire follow-up of 700 days, survival was more favorable (log-rank p < 0.0001), even after adjustment for age, gender and major comorbidities (Hazard Ratio (HR) 0.68; 95%CI 0.50-0.92). Within the CHD population, multivariable Cox regression revealed the following effects (HR and [95% CI]) on mortality: fistula (HR 6.97 [3.36-14.47]), cerebral embolus (HR 4.64 [2.08-10.35]), renal insufficiency (HR 3.44 [1.48-8.02]), Staphylococcus aureus as causative agent (HR 2.06 [1.11-3.81]) and failure to undertake surgery when indicated (HR 5.93 [3.15-11.18]). CHD patients with IE have a better outcome in terms of all-cause mortality. The observed high incidence of dental procedures prior to IE warrants further studies about the current use, need and efficacy of antibiotic prophylaxis in CHD patients.

Sections du résumé

BACKGROUND BACKGROUND
Congenital Heart Disease (CHD) predisposes to Infective Endocarditis (IE), but data about characterization and prognosis of IE in CHD patients is scarce.
METHODS METHODS
The ESC-EORP-EURO-ENDO study is a prospective international study in IE patients (n = 3111). In this pre-specified analysis, adult CHD patients (n = 365, 11.7%) are described and compared with patients without CHD (n = 2746) in terms of baseline characteristics and mortality.
RESULTS RESULTS
CHD patients (73% men, age 44.8 ± 16.6 years) were younger and had fewer comorbidities. Of the CHD patients, 14% had a dental procedure before hospitalization versus 7% in non-CHD patients (p < 0.001) and more often had positive blood cultures for Streptococcus viridans (16.4% vs 8.8%, p < 0.001). As in non-CHD patients, IE most often affected the left-sided valves. For CHD patients, in-hospital mortality was 9.0% vs 18.1% in non-CHD patients (p < 0.001), and also, during the entire follow-up of 700 days, survival was more favorable (log-rank p < 0.0001), even after adjustment for age, gender and major comorbidities (Hazard Ratio (HR) 0.68; 95%CI 0.50-0.92). Within the CHD population, multivariable Cox regression revealed the following effects (HR and [95% CI]) on mortality: fistula (HR 6.97 [3.36-14.47]), cerebral embolus (HR 4.64 [2.08-10.35]), renal insufficiency (HR 3.44 [1.48-8.02]), Staphylococcus aureus as causative agent (HR 2.06 [1.11-3.81]) and failure to undertake surgery when indicated (HR 5.93 [3.15-11.18]).
CONCLUSIONS CONCLUSIONS
CHD patients with IE have a better outcome in terms of all-cause mortality. The observed high incidence of dental procedures prior to IE warrants further studies about the current use, need and efficacy of antibiotic prophylaxis in CHD patients.

Identifiants

pubmed: 36273665
pii: S0167-5273(22)01647-3
doi: 10.1016/j.ijcard.2022.10.136
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

178-185

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

Joost P van Melle (JP)

Center for Congenital Heart Diseases, Department of Cardiology, University Medical Center Groningen, University of Groningen, the Netherlands. Electronic address: j.p.van.melle@umcg.nl.

Jolien W Roos-Hesselink (JW)

Department of Cardiology, Erasmus MC, Rotterdam, the Netherlands.

Manish Bansal (M)

Medanta, The Medicity, Gurgaon, Haryana 120001, India.

Otto Kamp (O)

Amsterdam UMC, Vrije Universiteit Amsterdam, Cardiology, Amsterdam Cardiovascular Sciences, the Netherlands.

Marwa Meshaal (M)

Department of Cardiology, Kasr Al Ainy Hospital, Faculty of Medicine, Cairo University, Cairo 11562, Egypt.

Jiri Pudich (J)

Department of Cardiovascular Diseases, University Hospital Ostrava, University of Ostrava, Faculty of Medicine, Czech Republic.

Vlatka Reskovic Luksic (VR)

Department of Cardiovascular Diseases, University of Zagreb, School of Medicine and University Hospital Centre Zagreb, Croatia.

Regino Rodriguez-Alvarez (R)

Infectious Diseases Unit, Cruces University Hospital, Barakaldo, Spain.

Anita Sadeghpour (A)

Echocardiography Research Center, Rajaie Cardiovascular Medical & Research Center, Tehran, Iran; Duke Cardiovascular MR Center, Durham, NC, United States of America.

Jadranka Separovic Hanzevacki (JS)

Department of Cardiovascular Diseases, University of Zagreb, School of Medicine and University Hospital Centre Zagreb, Croatia.

Rouguiatou Sow (R)

Department of Cardiology, Laboratory of Echocardiography, Luxembourg Hospital Centre, Luxembourg.

Ana Teresa Timóteo (AT)

Cardiology Department, Santa Marta Hospital, Centro Hospitalar Universitário Lisboa Central, Lisbon, Portugal.

Marisa Trabulo Morgado (MT)

Cardiology Department, Santa Cruz Hospital, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal.

Michele De Bonis (M)

Cardiac Surgery, IRCCS San Raffaele University Hospital, Milan, Italy.

Cecile Laroche (C)

EURObservational Research Programme, European Society of Cardiology, Heart House. 2035 Route des Colles, CS80179 Biot, 06903 Sophia-Antipolis, France.

Eric Boersma (E)

Department of Cardiology, Erasmus MC, Rotterdam, the Netherlands.

Patrizio Lancellotti (P)

University of Liège Hospital, GIGA Cardiovascular Sciences, Department of Cardiology, CHU Sart Tilman, Liège, Belgium; Gruppo Villa Maria Care and Research, Maria Cecilia Hospital, Cotignola, Anthea Hospital, Bari, Italy.

Gilbert Habib (G)

La Timone Hospital, Cardiology Department, Aix Marseille Univ, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH